BigHat Biosciences vs Nabla Bio (2026)
These two solve different halves of the antibody problem. BigHat Biosciences starts from a molecule that already exists, its own or a partner's, and improves it round by round, pairing machine learning with its own laboratory and describing itself as clinical stage. The work is optimization: take a lead and make it more developable, more potent, more manufacturable. Nabla Bio starts from nothing. Given a target and an epitope, its JAM system designs an antibody where none existed, and its focus is the membrane protein class where there is often no lead to start from. It publishes results target by target and has collaborations with AstraZeneca, Bristol Myers Squibb and Takeda, though no molecule has reached a trial yet. BigHat is the one when a team has a candidate and needs it engineered into a drug. Nabla is the one when there is no candidate yet and the target is one conventional methods struggle to address.
- Optimization of an existing antibody across developability, potency and manufacturability.
- A machine learning plus wet laboratory loop from a company describing itself as clinical stage.
- A fit for teams that already have a lead molecule and need it engineered forward.
- De novo design that produces an antibody where no lead exists, aimed at membrane targets.
- Results published target by target, including the targets the model missed.
- Collaborations with three large pharmaceutical companies against the platform.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. BigHat Biosciences and Nabla Bio are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | BigHat Biosciences | Nabla Bio |
|---|---|---|
| Primary category | Drug Discovery AI | Drug Discovery AI |
| Founded | 2019 | 2021 |
| Headquarters | San Mateo, California, United States | Cambridge, Massachusetts, United States |
| Website | bighatbio.com | nabla.bio |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards BigHat Biosciences its top capability grade on AI Centrality and Clinical and Operational Evidence. Set against Nabla Bio, BigHat Biosciences grades higher on Clinical and Operational Evidence, AI Safety and PHI Stewardship and Security Certifications and Trust Center. Its thinnest published disclosure sits on HIPAA and BAA Posture and EHR and Interoperability Depth. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, October 2026
The AI Health Index awards Nabla Bio its top capability grade on AI Centrality and AI Governance and Bias Disclosure. Set against BigHat Biosciences, Nabla Bio grades higher on AI Governance and Bias Disclosure and AI Liability and Recourse. Its thinnest published disclosure sits on several axes, including AI Safety and PHI Stewardship, HIPAA and BAA Posture and Security Certifications and Trust Center. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, October 2026
Questions buyers ask
Should we choose BigHat Biosciences or Nabla Bio?
On the axes where the AI Health Index separates them, BigHat Biosciences grades higher on Clinical and Operational Evidence, AI Safety and PHI Stewardship and Security Certifications and Trust Center, and Nabla Bio grades higher on AI Governance and Bias Disclosure and AI Liability and Recourse. BigHat Biosciences leads on the greater share of scored axes, but the split means the decision turns on which constraint is binding rather than on an overall winner.
Where do BigHat Biosciences and Nabla Bio differ most?
The widest separation the AI Health Index records between BigHat Biosciences and Nabla Bio is on Security Certifications and Trust Center, where BigHat Biosciences grades B and Nabla Bio grades D. That axis sits in the Regulatory and Compliance group, so it should carry the most weight for a buyer whose binding constraint is where regulatory exposure sits and who carries it.
Where do BigHat Biosciences and Nabla Bio grade the same?
The AI Health Index grades BigHat Biosciences and Nabla Bio the same on several axes, including AI Centrality, Autonomy and Oversight Model and Model and Technology Transparency. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
What have BigHat Biosciences and Nabla Bio not disclosed?
At the last review, at least one of BigHat Biosciences and Nabla Bio published thin or absent detail on several axes, including AI Safety and PHI Stewardship, HIPAA and BAA Posture and Security Certifications and Trust Center. The AI Health Index treats an absent disclosure as a gap in the public record rather than a failure of the product, so these are the axes to get in writing during diligence instead of inferring from the grade.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Drug Discovery AI page.
Both records were reviewed in October 2026. Neither publishes a price, and both run their own laboratories alongside partnered work.
Ask both where a design or optimization path has produced a molecule that advanced, and how each reports the rounds that did not pan out.